Common use of Global Development Committee Clause in Contracts

Global Development Committee. At such time as any Preclinical Development or clinical trial is undertaken by or under authority of Taiho or MG (including by an Additional Partner) anywhere in the world within the Field with respect to a Compound and/or Product outside of the Funded Work, the Parties shall establish a joint committee among MG, Taiho and any Additional Partner(s) to discuss and coordinate such development of such Compound and/or Product (the “Global Development Committee”). To the extent there are not Additional Partners, and if Funded Work is still ongoing at the time, the function of the Global Development Committee set forth in this Section 3.4 shall be handled by the JSC. The primary role of such Global Development Committee shall be to provide a forum for communication between MG, Taiho and any Additional Partner(s) with respect to activities related to the ongoing Preclinical Development and clinical development of Compounds and/or Products in the Field, outside the Funded Work. Taiho, MG and each Additional Partner having rights to such Compounds or Products shall each have at least two (2) representatives on such Global Development Committee. Each member of the Global Development Committee shall keep the other members fully informed in English (subject to Section 6.6) as to the ongoing Preclinical Development and clinical development of, and regulatory activities with respect to, such Compounds or Products in the Field. It is understood and agreed, however, that formal approval of such Global Development Committee shall not be required for any such activities. The Global Development Committee shall meet no less frequently than twice each calendar year, or as otherwise agreed by the Parties, until the termination or expiration of this Agreement and each of Taiho, MG and any Additional Party shall give a full report in English (subject to Section 6.6) at each such meeting of activities relating to the particular Compounds and Products such Party or Additional Partner has rights to that is undergoing Preclinical Development or clinical development in the Field. Additional Partners will participate in such meeting only with respect to Compounds and/or Products for which they have rights. It is further understood that MG shall not be deemed in breach of this Section 3.4 in the event an Additional Partner fails to comply with this Section 3.4, provided that MG has obtained in its agreement with such Additional Partner the obligation to comply with this Section 3.4, and has used reasonable efforts to cause such Additional Partner to comply with such agreement.

Global Development Committee. At such time as any Preclinical Development or and clinical trial development is undertaken by or under authority of Taiho Pharmion or MG (including by an Additional Partner) anywhere in the world within the Field with respect to a Compound and/or Product outside of the Funded WorkProduct, the Parties shall establish a joint committee among MG, Taiho Pharmion and any Additional Partner(s) to discuss and coordinate such development of such Compound and/or Product (the “Global Development Committee”). To the extent there are not Additional Partners, and if Funded Work is still ongoing at the time, the function of the Global Development Committee set forth in this Section 3.4 3.2 shall be handled by the JSC. The primary role of such Global Development Committee shall be to provide a forum for communication between MG, Taiho Pharmion and any Additional Partner(s) with respect to activities related to the ongoing Preclinical Development and clinical development of Compounds and/or Products in the Field, outside the Funded Work. TaihoPharmion, MG and each Additional Partner having rights to such Compounds or Products shall each have at least two (2) representatives on such Global Development Committee. Each member of the Global Development Committee shall keep the other members fully informed in English (subject to Section 6.6) as to the ongoing Preclinical Development and clinical development of, and regulatory activities with respect to, such Compounds or Products in the Field. It is understood and agreed, however, that formal approval of such Global Development Committee shall not be required for any such activities. The Global Development Committee shall meet no less frequently than twice each calendar year, or as otherwise agreed by the Parties, until the termination or expiration of this Agreement and each of TaihoPharmion, MG and any Additional Party shall give a full report in English (subject to Section 6.6) at each such meeting of activities relating to the particular Compounds and Products such Party or Additional Partner has rights to that is undergoing Preclinical Development or clinical development in the Field. Additional Partners will participate in such meeting only with respect to Compounds and/or Products for which they have rights. It is further understood that MG shall not be deemed in breach of this Section 3.4 3.2 in the event an Additional Partner fails to comply with this Section 3.43.2, provided that MG has obtained in its agreement with such Additional Partner the obligation to comply with this Section 3.43.2, and has used reasonable efforts to cause such Additional Partner to comply with such agreement. [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Global Development Committee. At such time as any Preclinical Development pre-clinical or clinical trial development is undertaken by or under authority of Taiho FemPharm or MG (including by an Additional Partner) any Acrux Controlled Affiliates anywhere in the world within the Field with respect to a Compound and/or Product (outside of the Funded WorkTerritory) for a Product within the Field, the Parties shall establish a joint committee among MGVivus, Taiho FemPharm (and/or the Acrux Controlled Affiliate, as the case may be) and any Additional Partner(s) to discuss and coordinate such development of such Compound and/or Product (the “"Global Development Committee”"). To the extent there are not no Additional Partners, and if Funded Work is still meetings of the Development Committee are ongoing at the time, the function of the Global Development Committee set forth in this Section 3.4 5.16 shall be handled by the JSCmembers of the Development Committee. The primary role of such Global Development Committee shall be to provide a forum for communication between MGVivus, Taiho FemPharm (and/or an Acrux Controlled Affiliate(s), as the case may be) and any Additional Partner(s) with respect to activities related to the ongoing Preclinical Development preclinical and clinical development of Compounds and/or Products in the Field, outside other than the Funded Workwork under the Development Plan under this Agreement. TaihoFemPharm, MG the Acrux Controlled Affiliates, Vivus, and each Additional Partner having rights to such Compounds or Products Product in the Field shall each have at least two (2) representatives on such Global Development Committee. Each member of the Global Development Committee shall keep the other members fully informed in English (subject to Section 6.65.17) as to the ongoing Preclinical Development preclinical and clinical development of, and regulatory activities with respect to, such Compounds or Products in the Field. It is understood and agreed, however, that formal approval of such Global Development Committee shall not be required for any such activities. The Global Development Committee shall meet no less frequently than twice each calendar year, or as otherwise agreed by the Parties, until the termination or expiration of this Agreement and each of TaihoVivus, MG FemPharm, Acrux Controlled Affiliates, and any Additional Party Parties shall give a full report in English (subject to Section 6.6) at each such meeting of activities relating to the particular Compounds and Products such Party or Additional Partner has rights to that is undergoing Preclinical Development or clinical development in the Field. Additional Partners will participate in such meeting only with respect to Compounds and/or Products for which they have rights. It is further understood that MG shall not be deemed in breach of this Section 3.4 in the event an Additional Partner fails to comply with this Section 3.4, provided that MG has obtained in its agreement with such Additional Partner the obligation to comply with this Section 3.4, and has used reasonable efforts to cause such Additional Partner to comply with such agreement.to